Evidence map›Paper›PMID 29579066›Full record

ArticlePloS one2018

Assessment of viral methylation levels for high risk HPV types by newly designed consensus primers PCR and pyrosequencing.

Anna Gillio-Tos, Valentina Fiano, Chiara Grasso, Morena Trevisan, Silvia Gori, Alessandra Mongia, Laura De Marco, Guglielmo Ronco, New Technologies for Cervical Cancer Screening (NTCC) Working Group

Registry-linked trialAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04687267 (Gestione Conservativa di Lesioni CIN2 e Valutazione di Biomarcatori Indicativi di Regressione), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04687267 completednot on this mapstarted 2019, after this paper: background citation

Gestione Conservativa di Lesioni CIN2 e Valutazione di Biomarcatori Indicativi di Regressione

TypeobservationalSponsorIstituto Oncologico Veneto IRCCSRan2019 to 2022Enrolled319ConditionsCIN2
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Genetic and Epigenetic Variations of HPV52 in Cervical Precancer.International journal of molecular sciences · 2021
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anna Gillio-TosCancer Epidemiology Unit-C.E.R.M.S, Department of Medical Sciences, University of Turin, Turin, Italy.ORCID 0000-0001-6553-5362
Valentina FianoCancer Epidemiology Unit-C.E.R.M.S, Department of Medical Sciences, University of Turin, Turin, Italy.
Chiara GrassoCancer Epidemiology Unit-C.E.R.M.S, Department of Medical Sciences, University of Turin, Turin, Italy.
Morena TrevisanCancer Epidemiology Unit-C.E.R.M.S, Department of Medical Sciences, University of Turin, Turin, Italy.
Silvia GoriImmunology and Diagnostic Molecular Oncology Unit, Veneto Institute of Oncology IOV IRCCS, Padua, Italy.
Alessandra MongiaRegional Cancer Prevention Laboratory-Oncological Network, Prevention and Research Institute (ISPRO), Florence, Italy.
Laura De MarcoCancer Epidemiology-CERMS, City of Health and Science Hospital and CPO, Turin, Italy.
Guglielmo RoncoCentre for Oncologic Prevention, Turin, Italy.
New Technologies for Cervical Cancer Screening (NTCC) Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMeasuring viral DNA methylation in human papillomavirus (HPV) infected women showed promise for accurate detection of high-grade cervical lesions and cancer. Methylation status has been widely investigated for HPV16, sporadically for other HPV types.

methodsObjective of this methodological study was to set up molecular methods to test the methylation levels in the twelve oncogenic HPV types by pyrosequencing, minimizing the number of HPV type-specific PCR protocols. Target CpGs were selected on the HPV L1 (two regions, L1 I and L1 II) and L2 genes. Study samples included DNA stored at Turin, Italy, purified by cervical cells collected in Standard Transport Medium or PreservCyt from women who participated in two studies (N = 126 and 140) nested within the regional organized screening programme. PCR consensus primers were designed by PyroMark Assay Design software to be suitable for amplification of many different oncogenic HPV types.

resultsGeneration of consensus primers was successful for L1 I and II regions, unsuccessful for L2 region, for which HPV type-specific primers remained necessary. The difference between replicated tests on the same sample was ≤4% in 88%, 77% and 91% of cases when targeting the L1 I, L1 II and L2 regions, respectively. The corresponding intra-class correlation coefficients (ICC) were 0.94, 0.87 and 0.97 respectively. When comparing methylation measures based on consensus and type-specific primers, ICC was 0.97 for the L1 I region and 0.99 the for L1 II region.

conclusionsThe proposed protocols, applying consensus primers suitable to amplify the oncogenic HPV types and minimize the number of PCR reactions, represent a promising tool to quantify viral methylation in women positive for any high risk HPV type. IMPACT: Potential application of these methylation protocols in screening settings can be explored to identify women with high probability of progression to high grade lesions.

Indexed as

DNA MethylationCapsid ProteinsCpG IslandsDNA PrimersDNA, ViralFemaleHumansPapillomaviridaePapillomavirus InfectionsPolymerase Chain ReactionReproducibility of ResultsRiskSequence Analysis, DNASoftwareCapsid ProteinsDNA PrimersDNA, Viral

Identifiers

PMID29579066
PMCPMC5868804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.